SecBot SecBot
S-3 ·Filed May 4, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-204134
Shelf registration, potential dilution
Actionable Insight • Neutral

Monitor for selling by RA Capital once the registration becomes effective. The out-of-the-money common stock warrants ($10 strike) limit immediate conversion risk, but the pre-funded warrants are essentially exercisable now. Watch for any filing of a 13D amendment or block trades from RA Capital.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.41
T+0 close · May 4, 2026 · via day close
Latest settled
−25.50%
T+60 · $7.01
Vs SPY
−28.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $9.41entry
  2. T+1 · 7mo ago 0.00%α −1.38% · $9.41
  3. T+5 · 6mo ago −6.38%α −8.36% · $8.81
  4. T+20 · 6mo ago −1.91%α −6.87% · $9.23
  5. T+60 · 4mo ago −25.50%α −28.24% · $7.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm filed an S-3 shelf registration for the resale of up to 8,843,036 shares by RA Capital Healthcare Fund, consisting of 1,030,354 outstanding shares, 3,391,164 pre-funded warrant shares, and 4,421,518 common stock warrant shares. The company will receive no proceeds from this resale; the filing fulfills registration rights granted in the March 2026 private placement that raised $30M. The common stock warrants have a $10 exercise price (currently out of the money at $8.40), so near-term selling is likely limited to the already-issued shares.

Key Facts

  • Registration covers 1,030,354 outstanding shares, 3,391,164 pre-funded warrant shares (exercise $0.0001), and 4,421,518 common stock warrant shares (exercise $10.00).
  • Company receives no proceeds from resale; gross proceeds from original March 2026 private placement were $30M.
  • Common stock warrants are out of the money (exercise $10 vs. current $8.40).
  • RA Capital is currently limited to beneficial ownership of 9.99% (2,290,108 shares) but may increase that limit upon 61 days' notice.

Financial Impact

No new capital raised; registered shares represent ~39% of current shares outstanding (22.55M), creating potential overhang but no immediate dilution from new issuance.

dilutionstock price

Risk Factors

  • Potential selling pressure from RA Capital's resale of the 1.03M outstanding shares and pre-funded warrant shares.
  • Further dilution if the common stock warrants are exercised (requires stock price above $10).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-204134
Document: d81858dex41.htm0001193125-26-204134
Document: d81858dex44.htm0001193125-26-204134

US Market Status

Market Closed · Opens in 8h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026